Profusa (NASDAQ:PFSA) Releases Earnings Results

Profusa (NASDAQ:PFSA) posted its earnings results on Friday. The company reported ($6.23) EPS for the quarter, FiscalAI reports.

Profusa Stock Down 2.6%

PFSA traded down $0.01 on Friday, hitting $0.45. 406,978 shares of the company traded hands, compared to its average volume of 2,762,980. Profusa has a 12-month low of $0.40 and a 12-month high of $1,539.75. The company has a 50 day moving average of $1.43 and a 200-day moving average of $62.72. The stock has a market capitalization of $271,488.00, a PE ratio of -0.00 and a beta of 0.62.

Analysts Set New Price Targets

PFSA has been the subject of a number of research reports. Wall Street Zen raised shares of Profusa to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings upgraded shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Profusa Company Profile

Profusa, Inc. is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling. The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.